Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Teladoc is a market leader in virtual care, but faces significant headwinds from increased competition and a strategic shift in its high-growth, direct-to-consumer mental health segment, BetterHelp.</li>
  <li>The company is transitioning its BetterHelp segment from a cash-pay model to an insurance-based one, which has caused near-term revenue declines but is expected to provide a more stable, long-term growth foundation.</li>
  <li>While the Integrated Care segment shows modest growth, overall financial performance has been hampered by the BetterHelp transition and profitability remains a key concern for investors, though free cash flow is a positive.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Teladoc is a market leader in virtual care, but faces significant headwinds from increased competition and a strategic shift in its high-growth, direct-to-consumer mental health segment, BetterHelp.
  The company is transitioning its BetterHelp segment from a cash-pay model to an insurance-based one, which has caused near-term revenue declines but is expected to provide a more stable, long-term growth foundation.
  While the Integrated Care segment shows modest growth, overall financial performance has been hampered by the BetterHelp transition and profitability remains a key concern for investors, though free cash flow is a positive.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Teladoc Health, Inc. (TDOC US) - Aug 2026

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Teladoc Health’s second quarter results for 2026 reflect continued progress in its Integrated Care segment alongside challenges and transition in its BetterHelp segment.</li><li>Consolidated revenue totaled $607 million with adjusted EBITDA of $66 million, representing a 10.8% margin.</li><li>The company reported a net loss per share of $0.21, including intangible amortization and stock-based compensation, while free cash flow was $36 million.</li></ul>

Teladoc Health’s second quarter results for 2026 reflect continued progress in its Integrated Care segment alongside challenges and transition in its BetterHelp segment.Consolidated revenue totaled $607 million with adjusted EBITDA of $66 million, representing a 10.8% margin.The company reported a net loss per share of $0.21, including intangible amortization and stock-based compensation, while free cash flow was $36 million.

Teladoc Health’s BetterHelp Insurance Revenue Surges 70% — Can It Replace Cash Pay?

<ul><li>Teladoc Health reported consolidated first-quarter 2026 revenue of $614 million and adjusted EBITDA of $58 million, corresponding to a 9.5% margin, with results exceeding the midpoint of prior guidance.</li><li>The Integrated Care segment contributed $395 million in revenue, a 1.5% increase year-over-year, driven by a high-single-digit rise in visit revenue and gains from acquisitions, though partially offset by lower subscription revenues.</li><li>International revenues grew in double digits, led by hybrid care models combining virtual and physical services.</li></ul>

Teladoc Health reported consolidated first-quarter 2026 revenue of $614 million and adjusted EBITDA of $58 million, corresponding to a 9.5% margin, with results exceeding the midpoint of prior guidance.The Integrated Care segment contributed $395 million in revenue, a 1.5% increase year-over-year, driven by a high-single-digit rise in visit revenue and gains from acquisitions, though partially offset by lower subscription revenues.International revenues grew in double digits, led by hybrid care models combining virtual and physical services.

Teladoc Health Is Not Just Virtual Care Anymore — Insurance Is The Pivot!

Research from ACF Equity Research, ACF Equity Research

ACF Equity Research

Research from ACF Equity Research

Accuracy | Clarity | Foresight

ACF was set up to improve the effectiveness of capital markets for smaller and mid-sized companies. The majority of jobs are created by smaller companies not global companies. If we can help improve companies use of capital markets more projects will be completed, more jobs created, more global GDP grown, which in turn helps create more resources for education, leading to equality and opportunity for those who are still oppressed by ignorance and poverty.

ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.

We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.

Our independent research is designed to educate our professional investor readers about your company, with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.

We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.

Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.

Thematic (Sector/Industry)

<ul>
<li>We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM).</li>
<li>We provide an investment case analysis and a selection of merged metrics prior to any synergies.</li>
<li>The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurodegenerative diseases (NDDs); and a clinical-stage Dual Orexin Receptor Agonist (DOXA) platform targets NDD therapies and metabolic disorders including ALS and sleep-wake disorders.</li>
</ul>


We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM).
We provide an investment case analysis and a selection of merged metrics prior to any synergies.
The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurodegenerative diseases (NDDs); and a clinical-stage Dual Orexin Receptor Agonist (DOXA) platform targets NDD therapies and metabolic disorders including ALS and sleep-wake disorders.


KDST + NLSP Combined Core Investment Case 29052025

<ul>
<li>Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market.</li>
<li>Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge.</li>
<li>Diabetes is a chronic metabolic disorder characterized by high blood sugar levels.</li>
</ul>


Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market.
Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge.
Diabetes is a chronic metabolic disorder characterized by high blood sugar levels.


ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innovation 13032025

United States

Teladoc Health, Inc. provides healthcare services. The Company diagnoses, recommends treatment, and prescribes medication for routine medical issues through phone and video consultations. Teladoc operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Teladoc Health, Inc. (TDOC US)

Primer: Teladoc Health, Inc. (TDOC US) - Aug 2026

Teladoc is a market leader in virtual care, but faces significant headwinds from increased competition and a strategic shift in its high-growth,...

αSK Primers

Teladoc Health’s BetterHelp Insurance Revenue Surges 70% — Can It Replace Cash Pay?

Teladoc Health’s second quarter results for 2026 reflect continued progress in its Integrated Care segment alongside challenges and transition in...

Baptista Research

Teladoc Health Is Not Just Virtual Care Anymore — Insurance Is The Pivot!

Teladoc Health reported consolidated first-quarter 2026 revenue of $614 million and adjusted EBITDA of $58 million, corresponding to a 9.5%...

Baptista Research

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of...

ACF Equity Research

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innovation 13032025

Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge.

ACF Equity Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)